Neurocrine Biosciences, Inc. (NBIX): Price and Financial Metrics

NBIX POWR Grades

• NBIX scores best on the Growth dimension, with a Growth rank ahead of 96.46% of US stocks.
• The strongest trend for NBIX is in Growth, which has been heading up over the past 178 days.
• NBIX's current lowest rank is in the Momentum metric (where it is better than 25.09% of US stocks).

NBIX Stock Summary

• NBIX's current price/earnings ratio is 208.64, which is higher than 97.82% of US stocks with positive earnings.
• Price to trailing twelve month operating cash flow for NBIX is currently 60.53, higher than 92.8% of US stocks with positive operating cash flow.
• With a year-over-year growth in debt of -39.19%, NEUROCRINE BIOSCIENCES INC's debt growth rate surpasses just 7.9% of about US stocks.
• Stocks that are quantitatively similar to NBIX, based on their financial statements, market capitalization, and price volatility, are UEC, FSLR, BMRN, AGYS, and NABL.
• Visit NBIX's SEC page to see the company's official filings. To visit the company's web site, go to www.neurocrine.com.

NBIX Valuation Summary

• NBIX's price/sales ratio is 8.8; this is 76% higher than that of the median Healthcare stock.
• NBIX's price/sales ratio has moved down 41.8 over the prior 243 months.

Below are key valuation metrics over time for NBIX.

NBIX Growth Metrics

The 4 year price growth rate now stands at 149.17%.
• Its year over year price growth rate is now at -3.49%.
• The 2 year net cashflow from operations growth rate now stands at -57.49%.

NBIX's revenue has moved up $1,065,418,000 over the prior 52 months.

The table below shows NBIX's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	1,388.7	200.6	58.2
2022-06-30	1,296.8	163.6	12.2
2022-03-31	1,207.5	128.7	71.4
2021-12-31	1,133.5	256.5	89.6
2021-09-30	1,069.4	341.2	444.8
2021-06-30	1,031.9	261.9	364.7

NBIX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• NBIX has a Quality Grade of B, ranking ahead of 78.08% of graded US stocks.
• NBIX's asset turnover comes in at 0.566 -- ranking 66th of 682 Pharmaceutical Products stocks.
• LGND, MNKD, and MRK are the stocks whose asset turnover ratios are most correlated with NBIX.

The table below shows NBIX's key quality metrics over time.